Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Reminds WWE, DRE, MN, and EPZM Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...